PharmaCyte Biotech Inc (PMCB)

[Peacefulwendy]

Here is a very nice list of accomplishments...

PMCB - On target for Phase IIB clinical trial and has destroyed all of the hurdles required to get to this point. Read the breakdown below for the things Ken Waggoner (KW) has completed in just over 2 years. First he had to fix the pile of garbage he was left with. A company with a product and no clue how to get it into trials. That alone takes time. KW made quick work of that and then did all of this leading up to today. The following will show that PMCB is not a scam and it has been moving forward towards clinical trials since KW walked in the door.

1-1-14 - KW officially takes over as President of NVLX

1-30-14 - NVLX immediately acquires 14.5% equity interest in Austrianova. First vision

3-20-14 - NVLX contracts with Austrianova to encapsulate cells for clinical trials.

4-1-14 - NVLX selects TD2 to conduct preclinical and clinical studies. i.e. the mice studies-

In 3 shorts months the relationship with Austrianova is solidified and the relationship with TD2 begins.

5-1-14 - NVLX and PMCB begin preclinical studies

7-9-14 - NVLX begins studies for treatment of Ascites Fluid

8-20-14 - TD2 joins NVLX to begin studies showing that CiaB can slow the accumulation of Ascites Fluid.

9-2-14 - NVLX submits application for ODD to EMA.

10-13-14 - NVLX submits application for ODD to FDA.

10-16-14 - NVLX secures world-wide license for Insulin producing cells for Diabetes.

11-24-16 -NVLX forms Diabetes Consortium with Professor Ann Simpson

12-4-14 - NVLX announces opening of Austrianova's cGMP Live Cell Encapsulation Facility.

12-18-14 - First live cell encapsulation at new facility just 14 days after it opens.

12-22-14 - FDA grants ODD to NVLX for Pancreatic Cancer with marketing exclusivity.

This is the end of 2014 and KW has done a ton including setting the base for everything PMCB is doing today. At this time clinical trials have not been scheduled yet.

1-7-15 - NVLX changes name to PharmaCyte Biotech.

2-15-15 - PMCB initiates first preclinical study of encapsulation of cells for Diabetes.

3-18-15 - PMCB finds in addition to everything else CiaB can do it can also consistently shrink tumors.

3-27-15 - PMCB begins talking clinical trial dates.

4-10-15 - Research shows that PMCB's Melligen Cell Line can reverse Diabetes.

4-20-15 - PMCB completes formation of International Diabetes Consortium to cure Diabetes.

5-6-15 - Melligen Cells prove safe in first preclinical test in Vienna.

7-16-15 - PMCB appoints Dr. Manuel Hidalgo to Scientific Advisory Board off of his work with CiaB in the preclinical studies at TD2.

8-15-15 - Interim Audit of cGMP facility is successful.

9-9-15 - PMCB brings Imagining Endpoints on-board to assist in Radiological Imaging for Phase IIB trials

Understand clinical trials could not have started until this last step was completed. As of September, 2014, PMCB was still waiting for cGMP approval for Austrianova's facility

10-21-15 - PMCB and TD2 begin to redesign trial design.

11-17-15 - PMCB obtains ODD from EMA and additional marketing exclusivity.

The year ends without a scheduled clinical trial with at this point a number of things not completed yet.


1-4-16 - KW outlines the rest of 2016 and has been checking off that self imposed list through-out the year. This includes trial set up for late 2016.

1-25-16 - PMCB and TD2 meet to re-design of the trial design.

2-14-16 - PMCB announces that trial still on target for late 2016.

3-31-16 - PMCB and TD2 finalize trial design and is completely re-written.

4-25-16 - cGMP finally granted by Thai Government with full go-ahead. Obviously PMCB has no control over how long it takes a country's government to approve a facility like this. Clinical Trials were never starting until this was done.

Keep in mind that this approval was only granted about 4 months ago and trials are still set for late 2016.

7-14-16 - PMCB receives patent protection of melligen cells to treat Diabetes. Diabetes will begin to play a bigger role once the Phase IIB trial is underway for Pancreatic Cancer.

At this point today we await the announcement of the Principal Investigator, IND application meeting and then a date for the start of clinical trials. It's easy to blame the CEO for the pps or the needed dilution to get to this point but unfortunately when you have just one product still in clinical trials, dilution is a necessary evil. No way around it. Until CiaB proves itself in humans, it will be difficult to sell another company on it's effectiveness. So, it is do whatever it takes to get to clinical trials. And that is exactly what they are doing. Getting CiaB into clinical trials. Once those results are in, the sky is the limit for PMCB and it's shareholders. The pps is low and well-below almost everyone's cost basis. However, you never lose money until you decide to sell your shares. Be smart. Believe in the Doctors and trust that PMCB is actually in the right hands. There will be value in the pps when PMCB is in trials and then the real value will come when there are buyout rumors and then going into trials for Diabetes. Hold those shares until trials start and begin seeing a gain from your investment.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124700885